NW-101C
/ Neowise Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 06, 2025
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Neowise Biotechnology
New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1